New delivery method lets cancer patients skip IVs, self-inject protein drugs at home.

Patients with cancer, autoimmune diseases, and metabolic disorders often endure hours-long intravenous infusions.

These treatments involve protein-based drugs, which must be given in high doses but remain stable only at low concentrations. Until now, IV infusions were the only option.

A Stanford research team has developed a delivery platform that changes this. The method allows protein drugs to be concentrated at far higher levels without losing stability.